Lupin receives tentative approval for Efinaconazole Topical Solution

26 Dec 2020 Evaluate

Lupin has received tentative approval for its Efinaconazole Topical Solution, 10%, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Jublia Topical Solution, 10%, of Bausch Health Americas, Inc.

Efinaconazole Topical Solution, 10%, is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes. Efinaconazole Topical Solution, 10%, (RLD: Jublia) had estimated annual sales of $222.9 million in the U.S. (IQVIA MAT September 2020).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2322.45 68.55 (3.04%)
20-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.45
Dr. Reddys Lab 1298.95
Cipla 1255.85
Zydus Lifesciences 890.60
Lupin 2322.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×